Umut Kocabaş1, Tarık Kıvrak2, Gülsüm Meral Yılmaz Öztekin3, Veysel Ozan Tanık4, Ibrahim Halil Özdemir5, Ersin Kaya6, Elif Ilkay Yüce7, Fulya Avcı Demir8, Mustafa Doğduş9, Meltem Altınsoy10, Songül Üstündağ11, Ferhat Özyurtlu12, Uğur Karagöz13, Alper Karakuş14, Örsan Deniz Urgun15, Ümit Yaşar Sinan16, Inan Mutlu17, Taner Şen18, Mehmet Ali Astarcıoğlu18, Mustafa Kınık19, Özge Özden Tok20, Begüm Uygur21, Mehtap Yeni22, Bahadır Alan23, Onur Dalgıç24, Çağla Sarıtürk25, Hakan Altay1, Seçkin Pehlivanoğlu1. 1. Department of Cardiology, Başkent University Istanbul Hospital, Istanbul, Turkey. 2. Department of Cardiology, Firat University, School of Medicine Hospital, Elazığ, Turkey. 3. Department of Cardiology, University of Health Sciences Antalya Training and Research Hospital, Antalya, Turkey. 4. Department of Cardiology, University of Health Sciences Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey. 5. Department of Cardiology, Nizip State Hospital, Gaziantep, Turkey. 6. Department of Cardiology, University of Health Sciences Dr Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital, Izmir, Turkey. 7. Department of Cardiology, Kelkit State Hospital, Gümüşhane, Turkey. 8. Department of Cardiology, Elmalı State Hospital, Antalya, Turkey. 9. Department of Cardiology, Karaman State Hospital, Karaman, Turkey. 10. Department of Cardiology, University of Health Sciences Ankara Atatürk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey. 11. Department of Cardiology, Erzincan Binali Yıldırım University, Mengücek Gazi Educatıon and Research Hospital, Erzincan, Turkey. 12. Department of Cardiology, Grandmedical Hospital, Manisa, Turkey. 13. Department of Cardiology, Izmir Katip Celebi University Atatürk Education and Research Hospital, Izmir, Turkey. 14. Department of Cardiology, Besni State Hospital, Adıyaman, Turkey. 15. Department of Cardiology, Adana Numune Education and Research Hospital, Adana, Turkey. 16. Department of Cardiology, Faculty of Medicine, Istanbul University, Institute of Cardiology, Istanbul,Turkey. 17. Department of Cardiology, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey. 18. Department of Cardiology, Kütahya Health Sciences University, School of Medicine, Kütahya, Turkey. 19. Department of Cardiology, Recep Tayyip Erdoğan University Training and Research Hospital, Rize, Turkey. 20. Department of Cardiology, Memorial Hospital, Istanbul, Turkey. 21. Department of Cardiology, University Of Health Sciences Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey. 22. Department of Cardiology, Isparta State Hospital, Isparta, Turkey. 23. Department of Cardiology, Okan University, School of Medicine, Istanbul, Turkey. 24. Department of Cardiology, Life Park Hospital, Sivas, Turkey. 25. Department of Biostatistics, Başkent University Adana Hospital, Adana, Turkey.
Abstract
OBJECTIVE: Despite recommendations from heart failure guidelines on the use of pharmacologic and device therapy in patients with heart failure with reduced ejection fraction (HFrEF), important inconsistencies in guideline adherence persist in practice. The aim of this study was to assess adherence to guideline-directed medical and device therapy for the treatment of patients with chronic HFrEF (left ventricular ejection fraction ≤40%). METHODS: The Adherence to guideline-directed medical and device Therapy in outpAtients with HFrEF (ATA) study is a prospective, multicenter, observational study conducted in 24 centers from January 2019 to June 2019. RESULTS: The study included 1462 outpatients (male: 70.1%, mean age: 67±11 years, mean LVEF: 30%±6%) with chronic HFrEF. Renin-angiotensin system (RAS) inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and ivabradin were used in 78.2%, 90.2%, 55.4%, and 12.1% of patients, respectively. The proportion of patients receiving target doses of medical treatments was 24.6% for RAS inhibitors, 9.9% for beta-blockers, and 10.5% for MRAs. Among patients who met the criteria for implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT), only 16.9% of patients received an ICD (167 of 983) and 34% (95 of 279) of patients underwent CRT (95 of 279). CONCLUSION: The ATA study shows that most HFrEF outpatients receive RAS inhibitors and beta-blockers but not MRAs or ivabradin when the medical reasons for nonuse, such as drug intolerance or contraindications, are taken into account. In addition, most eligible patients with HFrEF do not receive target doses of pharmacological treatments or guideline-recommended device therapy.
OBJECTIVE: Despite recommendations from heart failure guidelines on the use of pharmacologic and device therapy in patients with heart failure with reduced ejection fraction (HFrEF), important inconsistencies in guideline adherence persist in practice. The aim of this study was to assess adherence to guideline-directed medical and device therapy for the treatment of patients with chronic HFrEF (left ventricular ejection fraction ≤40%). METHODS: The Adherence to guideline-directed medical and device Therapy in outpAtients with HFrEF (ATA) study is a prospective, multicenter, observational study conducted in 24 centers from January 2019 to June 2019. RESULTS: The study included 1462 outpatients (male: 70.1%, mean age: 67±11 years, mean LVEF: 30%±6%) with chronic HFrEF. Renin-angiotensin system (RAS) inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and ivabradin were used in 78.2%, 90.2%, 55.4%, and 12.1% of patients, respectively. The proportion of patients receiving target doses of medical treatments was 24.6% for RAS inhibitors, 9.9% for beta-blockers, and 10.5% for MRAs. Among patients who met the criteria for implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT), only 16.9% of patients received an ICD (167 of 983) and 34% (95 of 279) of patients underwent CRT (95 of 279). CONCLUSION: The ATA study shows that most HFrEF outpatients receive RAS inhibitors and beta-blockers but not MRAs or ivabradin when the medical reasons for nonuse, such as drug intolerance or contraindications, are taken into account. In addition, most eligible patients with HFrEF do not receive target doses of pharmacological treatments or guideline-recommended device therapy.
Authors: María G Crespo-Leiro; Javier Segovia-Cubero; José González-Costello; Antoni Bayes-Genis; Silvia López-Fernández; Eulàlia Roig; Marisa Sanz-Julve; Carla Fernández-Vivancos; Manuel de Mora-Martín; José Manuel García-Pinilla; Alfonso Varela-Román; Luis Almenar-Bonet; Antonio Lara-Padrón; Luis de la Fuente-Galán; Juan Delgado-Jiménez Journal: Rev Esp Cardiol (Engl Ed) Date: 2015-05-21
Authors: J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong Journal: N Engl J Med Date: 1991-08-01 Impact factor: 91.245
Authors: Mehmet Birhan Yılmaz; Ahmet Çelik; Yüksel Çavuşoğlu; Lütfü Bekar; Ersel Onrat; Mehmet Eren; Merih Kutlu; Kenan Yalta; Ahmet Temizhan; Barış Kılıçaslan; Hasan Güngör; Mahmut Açıkel; Mesut Demir; Ramazan Akdemir; Mehdi Zoghi; Lale Tokgözoğlu Journal: Turk Kardiyol Dern Ars Date: 2019-04
Authors: James B Young; Mark E Dunlap; Marc A Pfeffer; Jeffrey L Probstfield; Alain Cohen-Solal; Rainer Dietz; Christopher B Granger; Jaromir Hradec; Jerzy Kuch; Robert S McKelvie; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Peter Held; Scott D Solomon; Salim Yusuf; Karl Swedberg Journal: Circulation Date: 2004-10-18 Impact factor: 29.690
Authors: Dirk J van Veldhuisen; Alexander H Maass; Silvia G Priori; Pelle Stolt; Isabelle C van Gelder; Kenneth Dickstein; Karl Swedberg Journal: Eur J Heart Fail Date: 2009-11-01 Impact factor: 15.534
Authors: Muzaffer Değertekin; Cetin Erol; Oktay Ergene; Lale Tokgözoğlu; Mehmet Aksoy; Mustafa Kemal Erol; Mehmet Eren; Mahmut Sahin; Elif Eroğlu; Bülent Mutlu; Omer Kozan Journal: Turk Kardiyol Dern Ars Date: 2012-06
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Reem K Jan; Alawi Alsheikh-Ali; Arif Al Mulla; Kadhim Sulaiman; Prashanth Panduranga; Wael Al-Mahmeed; Nooshin Bazargani; Jassim Al-Suwaidi; Mohammed Al-Jarallah; Ahmed Al-Motarreb; Amar Salam; Ibrahim Al-Zakwani Journal: Medicine (Baltimore) Date: 2022-06-10 Impact factor: 1.817